ESOPMay 7, 2026, 04:32 PM
Xilio Therapeutics Grants 1,982 Stock Options to New Employee at $8.32
AI Summary
Xilio Therapeutics, Inc. announced that it granted non-qualified stock options to purchase 1,982 shares of its common stock to one new employee. The grant was made effective May 1, 2026, under the company's 2022 Inducement Stock Incentive Plan. The options have an exercise price of $8.32 per share, equal to the closing price on the grant date, and will vest over a four-year period. This action was taken as an inducement material to the individual's employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Key Highlights
- Xilio Therapeutics granted non-qualified stock options for 1,982 shares of common stock.
- Options were issued to one new employee under the 2022 Inducement Stock Incentive Plan.
- The exercise price is $8.32 per share, matching the closing price on May 1, 2026.
- The stock options have a ten-year term.
- Vesting schedule: 25% on the first anniversary, then 75% in 36 equal monthly installments.
- The grant serves as an inducement for employment, per Nasdaq Listing Rule 5635(c)(4).
Price Impact
More from XLO